Oxaliplatin-induced neurotoxicity is mediated through gap junction channels and hemichannels and can be prevented by octanol

Neuropharmacology

Volumn 97, Issue , 2015, Pages 289-305

  Kagiava, Alexia ^a   Theophilidis, George ^b   Sargiannidou, Irene ^a   Kyriacou, Kyriacos ^a   Kleopa, Kleopas A ^a  

^a CYPRUS INSTITUTE OF NEUROLOGY AND GENETICS   (Cyprus)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Action potential; Chemotherapy induced neuropathy; Cx29; Cx32; Gap junctions; Juxtaparanodes; Sciatic nerve

Indexed keywords

CARBENOXOLONE; CONNEXIN 32; GAP JUNCTION PROTEIN; OCTANOL; POTASSIUM ION; PROTEIN CX29; UNCLASSIFIED DRUG; GJC3 PROTEIN, HUMAN; GJE1 PROTEIN, MOUSE; NERVE PROTEIN; NEUROPROTECTIVE AGENT; OXALIPLATIN; PLATINUM COMPLEX; POTASSIUM;

ACTION POTENTIAL; AMPLITUDE MODULATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; EX VIVO STUDY; GAP JUNCTION; HELA CELL LINE; HOMEOSTASIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROANATOMY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXALIPLATIN INDUCED NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REPOLARIZATION; SCIATIC NERVE; ANIMAL; ANTAGONISTS AND INHIBITORS; AXON; C57BL MOUSE; DOSE RESPONSE; DRUG EFFECTS; EDEMA; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; AXONS; CONNEXINS; DOSE-RESPONSE RELATIONSHIP, DRUG; EDEMA; HELA CELLS; HOMEOSTASIS; HUMANS; MICE, INBRED C57BL; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; OCTANOLS; ORGANOPLATINUM COMPOUNDS; POTASSIUM; SCIATIC NERVE;

EID: 84933039027     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2015.05.021     Document Type: Article

References (101)

1. H. Adelsberger, S. Quasthoff, J. Grosskreutz, A. Lepier, F. Eckel, and C. Lersch The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons Eur. J. Pharmacol. 406 2000 25 32
2. B.M. Altevogt, K.A. Kleopa, F.R. Postma, S.S. Scherer, and D.L. Paul Connexin29 is uniquely distributed within myelinating glial cells of the central and peripheral nervous systems J. Neurosci. 22 2002 6458 6470
3. T. Andre, C. Boni, L. Mounedji-Boudiaf, M. Navarro, J. Tabernero, T. Hickish, C. Topham, M. Zaninelli, P. Clingan, J. Bridgewater, I. Tabah-Fisch, A. de Gramont Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer I Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer N. Engl. J. Med. 350 2004 2343 2351
4. P. Anzini, D.H.-H. Neuberg, M. Schachner, E. Nelles, K. Willecke, J. Zielasek, K. Toyka, U. Suter, and R. Martini Structural abnormalities and deficient maintenance of peripheral nerve myelin in mice lacking the gap junction protein connexin32 J. Neurosci. 17 1997 4545 4561
5. M. Aoki, A. Mori, T. Nakahara, K. Sakamoto, and K. Ishii Effect of synthetic eel calcitonin, elcatonin, on cold and mechanical allodynia induced by oxaliplatin and paclitaxel in rats Eur. J. Pharmacol. 696 2012 62 69
6. A.A. Argyriou, G. Cavaletti, A. Antonacopoulou, A.A. Genazzani, C. Briani, J. Bruna, S. Terrazzino, R. Velasco, P. Alberti, M. Campagnolo, S. Lonardi, D. Cortinovis, M. Cazzaniga, C. Santos, A. Psaromyalou, A. Angelopoulou, and H.P. Kalofonos Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study Cancer 119 2013 3570 3577
7. M.L. Astion, J.A. Coles, R.K. Orkand, and N.J. Abbott K+ accumulation in the space between giant axon and Schwann cell in the squid Alloteuthis. Effects of changes in osmolarity Biophys. J. 53 1988 281 285
8. M.D. Baker, and J.M. Ritchie Characteristics of type I and type II K+ channels in rabbit cultured Schwann cells J. Physiol. 490 1996 79 95
9. R.J. Balice-Gordon, L.J. Bone, and S.S. Scherer Functional gap junctions in the Schwann cell myelin sheath J. Cell Biol. 142 1998 1095 1104
10. M. Beaumont, and G. Maccaferri Is connexin36 critical for GABAergic hypersynchronization in the hippocampus? J. Physiol. 589 2011 1663 1680
11. E. Benoit, S. Brienza, and J.M. Dubois Oxaliplatin, an anticancer agent that affects both Na+ and K+ channels in frog peripheral myelinated axons Gen. Physiol. Biophys. 25 2006 263 276
12. J. Boyette-Davis, and P.M. Dougherty Protection against oxaliplatin-induced mechanical hyperalgesia and intraepidermal nerve fiber loss by minocycline Exp. Neurol. 229 2011 353 357
13. M.E.T. Boyle, E.O. Berglund, K.K. Murai, L. Weber, E. Peles, and B. Ranscht Contactin orchestrates assembly of the septate-like junctions at the paranode in myelinated peripheral nerve Neuron 30 2001 385 397
14. A. Broomand, E. Jerremalm, J. Yachnin, H. Ehrsson, and F. Elinder Oxaliplatin neurotoxicity - no general ion channel surface-charge effect J. Negat. Results Biomed. 8 2009 2
15. R. Bruzzone, M.T. Barbe, N.J. Jakob, and H. Monyer Pharmacological properties of homomeric and heteromeric pannexin hemichannels expressed in Xenopus oocytes J. Neurochem. 92 2005 1033 1043
16. F.F. Bukauskas, and R. Weingart Temperature dependence of gap junction properties in neonatal rat heart cells Pflug. Arch. 423 1993 133 139
17. A.Z. Burakgazi, W. Messersmith, D. Vaidya, P. Hauer, A. Hoke, and M. Polydefkis Longitudinal assessment of oxaliplatin-induced neuropathy Neurology 77 2011 980 986
18. K.O. Bushara, S.R. Goldstein, G.J. Grimes Jr., A.H. Burstein, and M. Hallett Pilot trial of 1-octanol in essential tremor Neurology 62 2004 122 124
19. X.F. Chen, R. Wang, Y.M. Yin, O.D. Roe, J. Li, L.J. Zhu, R.H. Guo, T. Wu, and Y.Q. Shu The effect of monosialotetrahexosylganglioside (GM1) in prevention of oxaliplatin induced neurotoxicity: a retrospective study Biomed. Pharmacother. 66 2012 279 284
20. S.Y. Chiu Functions and distribution of voltage-gated sodium and potassium channels in mammalian Schwann cells Glia 4 1991 541 558
21. J.E. Contreras, J.C. Sáez, F.F. Bukauskas, and M.V. Bennett Gating and regulation of connexin 43 (Cx43) hemichannels Proc. Natl. Acad. Sci. U. S. A. 100 2003 11388 11393
22. J.O. Davidson, P.P. Drury, C.R. Green, L.F. Nicholson, L. Bennet, and A.J. Gunn Connexin hemichannel blockade is neuroprotective after asphyxia in preterm fetal sheep PLoS One 9 5 2014 e96558
23. L. Di Cesare Mannelli, M. Z, P. Failli, and C. Ghelardini Oxaliplatin-induced neuropathy: oxidative stress as pathological mechanism. Protective effect of silibinin J. Pain 13 2012 276 284
24. A.G. Dimitrov, and N.A. Dimitrova A possible link of oxaliplatin-induced neuropathy with potassium channel deficit Muscle Nerve 45 2012 403 411
25. F. Eckel, R. Schmelz, H. Adelsberger, J. Erdmann, S. Quasthoff, and C. Lersch Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study Dtsch. Med. Wochenschr. 127 2002 78 82
26. J. Eiberger, M. Kibschull, N. Strenzke, A. Schober, H. Büssow, C. Wessig, S. Djahed, H. Reucher, D.A. Koch, J. Lautermann, T. Moser, E. Winterhager, and K. Willecke Expression pattern and functional characterization of connexin29 in transgenic mice Glia 53 2006 601 611
27. S. Eskandari, G.A. Zampighi, D.W. Leung, E.M. Wright, and D.D. Loo Inhibition of gap junction hemichannels by chloride channel blockers J. Membr. Biol. 185 2002 93 102
28. I. Fasciani, A. Temperan, L.F. Perez-Atencio, A. Escudero, P. Martinez-Montero, J. Molano, J.M. Gomez-Hernandez, C.L. Paino, D. Gonzalez-Nieto, and L.C. Barrio Regulation of connexin hemichannel activity by membrane potential and the extracellular calcium in health and disease Neuropharmacology 75 2013 479 490
29. J. Ferrier, V. Pereira, J. Busserolles, N. Authier, and D. Balayssac Emerging trends in understanding chemotherapy-induced peripheral neuropathy Curr. Pain Headache Rep. 17 2013 364
30. S.J. Flatters, and G.J. Bennett Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy Pain 109 2004 150 161
31. P. Gomes, S.P. Srinivas, W. Van Driessche, J. Vereecke, and B. Himpens ATP release through connexin hemichannels in corneal endothelial cells Invest. Ophthalmol. Vis. Sci. 46 2005 1208 1218
32. M.A. Graham, G.F. Lockwood, D. Greenslade, S. Brienza, M. Bayssas, and E. Gamelin Clinical pharmacokinetics of oxaliplatin: a critical review Clin. Cancer Res. 6 2000 1205 1218
33. F. Grolleau, L. Gamelin, M. Boisdron-Celle, B. Lapied, M. Pelhate, and E. Gamelin A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels J. Neurophysiol. 85 2001 2293 2297
34. P.T. Hargittai, S.J. Youmans, and E.M. Lieberman Determination of the membrane potential of cultured mammalian Schwann cells and its sensitivity to potassium using a thiocarbocyanine fluorescent dye Glia 4 1991 611 616
35. I.K. Hart, P. Maddison, J. Newsom-Davis, A. Vincent, and K.R. Mills Phenotypic variants of autoimmune peripheral nerve hyperexcitability Brain 125 2002 1887 1895
36. D. Haubenberger, F.B. Nahab, B. Voller, and M. Hallet Treatment of essential tremor with long-chain alcohols: still experimental or ready for prime time? Tremor Other Hyperkinetic Mov. 2014 10.7916/D8RX991R
37. H.S. Hochster, A. Grothey, and B.H. Childs Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity J. Clin. Oncol. 25 2007 4028 4029
38. Y. Horio Potassium channels of glial cells: distribution and function Jpn. J. Pharmacol. 87 2001 1 6
39. T. Horishita, and R.A. Harris n-Alcohols inhibit voltage-gated Na+ channels expressed in Xenopus oocytes J. Pharmacol. Exp. Ther. 326 2008 270 277
40. A. Kagiava, K. Aligizaki, P. Katikou, G. Nikolaidis, and G. Theophilidis Assessing the neurotoxic effects of palytoxin and ouabain, both Na(+)/K(+)-ATPase inhibitors, on the myelinated sciatic nerve fibres of the mouse: an ex vivo electrophysiological study Toxicon 59 2012 416 426
41. A. Kagiava, E.K. Kosmidis, and G. Theophilidis Oxaliplatin-induced hyperexcitation of rat sciatic nerve fibers: an intra-axonal study Anticancer Agents Med. Chem. 13 2013 373 379
42. A. Kagiava, A. Tsingotjidou, C. Emmanouilides, and G. Theophilidis The effects of oxaliplatin, an anticancer drug, on potassium channels of the peripheral myelinated nerve fibres of the adult rat Neurotoxicology 29 2008 1100 1106
43. J. Kang, N. Kang, D. Lovatt, A. Torres, Z. Zhao, J. Lin, and M. Nedergaard Connexin 43 hemichannels are permeable to ATP J. Neurosci. 28 2008 4702 4711
44. T. Kawashiri, N. Egashira, Y. Itoh, T. Shimazoe, Y. Ikegami, T. Yano, M. Yoshimura, and R. Oishi Neurotropin reverses paclitaxel-induced neuropathy without affecting anti-tumour efficacy Eur. J. Cancer 45 2009 154 163
45. T. Kawashiri, N. Egashira, H. Watanabe, Y. Ikegami, S. Hirakawa, Y. Mihara, T. Yano, H. Ikesue, and R. Oishi Prevention of oxaliplatin-induced mechanical allodynia and neurodegeneration by neurotropin in the rat model Eur. J. Pain 15 2011 344 350
46. W. Kern, J. Braess, B. Bottger, C.C. Kaufmann, W. Hiddemann, and E. Schleyer Oxaliplatin pharmacokinetics during a four-hour infusion Clin. Cancer Res. 5 1999 761 765
47. K.A. Kleopa The role of gap junctions in Charcot-Marie-Tooth disease J. Neurosci. 31 2011 17753 17760
48. K.A. Kleopa, L.B. Elman, B. Lang, A. Vincent, and S.S. Scherer Neuromyotonia and limbic encephalitis sera target mature Shaker-type K+ channels: subunit specificity correlates with clinical manifestations Brain 129 2006 1570 1584
49. J.D. Kocsis, D.L. Eng, T.R. Gordon, and S.G. Waxman Functional differences between 4-aminopyridine and tetraethylammonium-sensitive potassium channels in myelinated axons Neurosci. Lett. 75 1987 193 198
50. T. Konishi Voltage-gated potassium currents in myelinating Schwann cells in the mouse J. Physiol. 431 1990 123 139
51. A.V. Krishnan, D. Goldstein, M. Friedlander, and M.C. Kiernan Oxaliplatin and axonal Na+ channel function in vivo Clin. Cancer Res. 12 2006 4481 4484
52. T. Krøigård, H.D. Schrøder, C. Qvortrup, L. Eckhoff, P. Pfeiffer, D. Gaist, and S.H. Sindrup Characterization and diagnostic evaluation of chronic polyneuropathies induced by oxaliplatin and docetaxel comparing skin biopsy to quantitative sensory testing and nerve conduction studies Eur. J. Neurol. 21 2014 623 629
53. J. Kume-Kick, T. Mazel, I. Vorisek, S. Hrabetova, L. Tao, and C. Nicholson Independence of extracellular tortuosity and volume fraction during osmotic challenge in rat neocortex J. Physiol. 542 2002 515 527
54. D.M. Kweekel, H. Gelderblom, and H.J. Guchelaar Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy Cancer Treat. Rev. 31 2005 90 105
55. P.M. Lang, J. Fleckenstein, G.M. Passmore, D.A. Brown, and P. Grafe Retigabine reduces the excitability of unmyelinated peripheral human axons Neuropharmacology 54 2008 1271 1278
56. T.J. Lehky, G.D. Leonard, R.H. Wilson, J.L. Grem, and M.K. Floeter Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy Muscle Nerve 29 2004 387 392
57. V. Lev-Ram, and M.H. Ellisman Axonal activation-induced calcium transients in myelinating Schwann cells, sources, and mechanisms J. Neurosci. 15 1995 2628 2637
58. C.L. Loprinzi, R. Qin, S.R. Dakhil, L. Fehrenbacher, K.A. Flynn, P. Atherton, D. Seisler, R. Qamar, G.C. Lewis, and A. Grothey Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance) J. Clin. Oncol. 32 2014 997 1005
59. D.M. Menichella, M. Majdan, R. Awatramani, D.A. Goodenough, E. Sirkowski, S.S. Scherer, and D.L. Paul Genetic and physiological evidence that oligodendrocyte gap junctions contribute to spatial buffering of potassium released during neuronal activity J. Neurosci. 26 2006 10984 10991
60. H. Mi, T.J. Deerinck, M. Jones, M.H. Ellisman, and T.L. Schwarz Inwardly rectifying K+ channels that may participate in K+ buffering are localized in microvilli of Schwann cells J. Neurosci. 16 1996 2421 2429
61. H. Nodera, A. Spieker, M. Sung, and S. Rutkove Neuroprotective effects of Kv7 channel agonist, retigabine, for cisplatin-induced peripheral neuropathy Neurosci. Lett. 505 2011 223 227
62. J.A. Orellana, D.E. Hernández, P. Ezan, V. Velarde, M.V. Bennett, C. Giaume, and J.C. Sáez Hypoxia in high glucose followed by reoxygenation in normal glucose reduces the viability of cortical astrocytes through increased permeability of connexin 43 hemichannels Glia 58 2010 329 343
63. S.B. Park, C.S. Lin, A.V. Krishnan, D. Goldstein, M.L. Friedlander, and M.C. Kiernan Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy Brain 132 2009 2712 2723
64. S.B. Park, C.S. Lin, A.V. Krishnan, D. Goldstein, M.L. Friedlander, and M.C. Kiernan Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity PLoS One 6 2011 e18469
65. D.L. Paul, L. Ebihara, L.J. Takemoto, K.I. Swenson, and D.A. Goodenough Voltage gating and permeation in a gap junction hemichannel J. Cell Biol. 115 1991 1077 1089
66. S. Poliak, D. Salomon, H. Elhanany, H. Sabanay, B. Kiernan, L. Pevny, C.L. Stewart, X. Xu, S.Y. Chiu, P. Shrager, A.J. Furley, and E. Peles Juxtaparanodal clustering of Shaker-like K+ channels in myelinated axons depends on Caspr2 and TAG-1 J. Cell Biol. 162 2003 1149 1160
67. D. Poyraz, M.E. Bräu, F. Wotka, B. Puhlmann, A.M. Scholz, G. Hempelmann, W.J. Kox, and C.D. Spies Lidocaine and octanol have different modes of action at tetrodotoxin-resistant Na(+) channels of peripheral nerves Anesth. Analg. 97 2003 1317 1324
68. A.P. Quist, S.K. Rhee, H. Lin, and R. Lal Physiological role of gap-junctional hemichannels. Extracellular calcium-dependent isosmotic volume regulation J. Cell Biol. 148 2000 1063 1074
69. M.N. Rasband, E.W. Park, D. Zhen, M.I. Arbuckle, S. Poliak, E. Peles, S.G. Grant, and J.S. Trimmer Clustering of neuronal potassium channels is independent of their interaction with PSD-95 J. Cell Biol. 159 2002 663 672
70. J.E. Rash Molecular disruptions of the panglial syncytium block potassium siphoning and axonal saltatory conduction: pertinence to neuromyelitis optica and other demyelinating diseases of the central nervous system Neuroscience 168 2010 982 1008
71. M.A. Retamal, N. Froger, N. Palacios-Prado, P. Ezan, P.J. Saez, J.C. Saez, and C. Giaume Cx43 hemichannels and gap junction channels in astrocytes are regulated oppositely by proinflammatory cytokines released from activated microglia J. Neurosci. 27 2007 13781 13792
72. N. Rouach, M. Segal, A. Koulakoff, C. Giaume, and E. Avignone Carbenoxolone blockade of neuronal network activity in culture is not mediated by an action on gap junctions J. Physiol. 553 2003 729 745
73. P. Saitongdee, P. Milner, D.L. Becker, G.E. Knight, and G. Burnstock Increased connexin43 gap junction protein in hamster cardiomyocytes during cold acclimatization and hibernation Cardiovasc. Res. 47 2000 108 115
74. M. Sakurai, N. Egashira, T. Kawashiri, T. Yano, H. Ikesue, and R. Oishi Oxaliplatin-induced neuropathy in the rat: involvement of oxalate in cold hyperalgesia but not mechanical allodynia Pain 147 2009 165 174
75. I. Sargiannidou, M. Ahn, A.D. Enriquez, A. Peinado, R. Reynolds, C. Abrams, S.S. Scherer, and K.A. Kleopa Human oligodendrocytes express Cx31.3: function and interactions with Cx32 mutants Neurobiol. Dis. 30 2008 221 233
76. I. Sargiannidou, N. Vavlitou, S. Aristodemou, A. Hadjisavvas, K. Kyriacou, S.S. Scherer, and K.A. Kleopa Connexin32 mutations cause loss of function in Schwann cells and oligodendrocytes leading to PNS and CNS myelination defects J. Neurosci. 29 2009 4748 4761
77. S.S. Scherer, S.M. Deschenes, Y.T. Xu, J.B. Grinspan, K.H. Fischbeck, and D.L. Paul Connexin32 is a myelin-related protein in the PNS and CNS J. Neurosci. 15 1995 8281 8294
78. S.S. Scherer, Y.-T. Xu, E. Nelles, K. Fischbeck, K. Willecke, and L.J. Bone Connexin32-null mice develop a demyelinating peripheral neuropathy Glia 24 1998 8 20
79. A. Scuteri, A. Galimberti, M. Ravasi, S. Pasini, E. Donzelli, G. Cavaletti, and G. Tredici NGF protects dorsal root ganglion neurons from oxaliplatin by modulating JNK/Sapk and ERK1/2 Neurosci. Lett. 486 2010 141 145
80. R. Sittl, R.W. Carr, J. Fleckenstein, and P. Grafe Enhancement of axonal potassium conductance reduces nerve hyperexcitability in an in vitro model of oxaliplatin-induced acute neuropathy Neurotoxicology 31 2010 694 700
81. K.E. Spong, and R.M. Robertson Pharmacological blockade of gap junctions induces repetitive surging of extracellular potassium within the locust CNS J. Insect Physiol. 59 2013 1031 1040
82. D.C. Spray, J.C. Saez, D. Brosius, M.V. Bennett, and E.L. Hertzberg Isolated liver gap junctions: gating of transjunctional currents is similar to that in intact pairs of rat hepatocytes Proc. Natl. Acad. Sci. U. S. A. 83 1986 5494 5497
83. S.O. Suadicani, C.F. Brosnan, and E. Scemes P2X7 receptors mediate ATP release and amplification of astrocytic intercellular Ca2+ signaling J. Neurosci. 26 2006 1378 1385
84. W. Tang, Y. Zhang, Q. Chang, S. Ahmad, I. Dahlke, H. Yi, P. Chen, D.L. Paul, and X. Lin Connexin29 is highly expressed in cochlear Schwann cells, and it is required for the normal development and function of the auditory nerve of mice J. Neurosci. 26 2006 1991 1999
85. Y. Tatsushima, N. Egashira, Y. Narishige, S. Fukui, T. Kawashiri, Y. Yamauchi, and R. Oishi Calcium channel blockers reduce oxaliplatin-induced acute neuropathy: a retrospective study of 69 male patients receiving modified FOLFOX6 therapy Biomed. Pharmacother. 67 2013 39 42
86. K.R. Tovar, B.J. Maher, and G.L. Westbrook Direct actions of carbenoxolone on synaptic transmission and neuronal membrane properties J. Neurophysiol. 102 2009 974 978
87. M. Traka, L. Goutebroze, N. Denisenko, M. Bessa, A. Nifli, S. Havaki, Y. Iwakura, F. Fukamauchi, K. Watanabe, B. Soliven, J.A. Girault, and D. Karagogeos Association of TAG-1 with Caspr2 is essential for the molecular organization of juxtaparanodal regions of myelinated fibers J. Cell Biol. 162 2003 1161 1172
88. E.B. Trexler, M.V. Bennett, T.A. Bargiello, and V.K. Verselis Voltage gating and permeation in a gap junction hemichannel Proc. Natl. Acad. Sci. U. S. A. 93 1996 5836 5841
89. S. Ushio, N. Egashira, H. Sada, T. Kawashiri, M. Shirahama, K. Masuguchi, and R. Oishi Goshajinkigan reduces oxaliplatin-induced peripheral neuropathy without affecting anti-tumour efficacy in rodents Eur. J. Cancer 48 2012 1407 1413
90. I. Vabnick, J.S. Trimmer, T.L. Schwarz, S.R. Levinson, D. Risal, and P. Shrager Dynamic potassium channel distributions during axonal development prevent aberrant firing patterns J. Neurosci. 19 1999 747 758
91. V. Valiunas, and R. Weingart Electrical properties of gap junction hemichannels identified in transfected HeLa cells Pflug. Arch. 440 2000 366 379
92. M. Van Poucke, A.E. Vanhaesebrouck, L.J. Peelman, and L. Van Ham Experimental validation of in silico predicted KCNA1, KCNA2, KCNA6 and KCNQ2 genes for association studies of peripheral nerve hyperexcitability syndrome in Jack Russell Terriers Neuromuscul. Disord. 22 2012 558 565
93. N. Vavlitou, I. Sargiannidou, K. Markoullis, K. Kyriacou, S.S. Scherer, and K.A. Kleopa Axonal pathology precedes demyelination in a mouse model of X-linked demyelinating/type I Charcot-Marie Tooth neuropathy J. Neuropathol. Exp. Neurol. 69 2010 945 958
94. V.K. Verselis, and M. Srinivas Connexin channel modulators and their mechanisms of action Neuropharmacology 75 2013 517 524
95. J.P. Vessey, M.R. Lalonde, H.A. Mizan, N.C. Welch, M.E. Kelly, and S. Barnes Carbenoxolone inhibition of voltage-gated Ca channels and synaptic transmission in the retina J. Neurophysiol. 92 2004 1252 1256
96. S. von Delius, F. Eckel, S. Wagenpfeil, M. Mayr, K. Stock, F. Kullmann, F. Obermeier, J. Erdmann, R. Schmelz, S. Quasthoff, H. Adelsberger, R. Bredenkamp, R.M. Schmid, and C. Lersch Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study Invest. New Drugs 25 2007 173 180
97. R.A. Warwick, and M. Hanani The contribution of satellite glial cells to chemotherapy-induced neuropathic pain Eur. J. Pain 17 2013 571 580
98. R.G. Webster, K.L. Brain, R.H. Wilson, J.L. Grem, and A. Vincent Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels Br. J. Pharmacol. 146 2005 1027 1039
99. R.H. Wilson, T. Lehky, R.R. Thomas, M.G. Quinn, M.K. Floeter, and J.L. Grem Acute oxaliplatin-induced peripheral nerve hyperexcitability J. Clin. Oncol. 20 2002 1767 1774
100. S.Y. Yoon, C.R. Robinson, H. Zhang, and P.M. Dougherty Spinal astrocyte gap junctions contribute to oxaliplatin-induced mechanical hypersensitivity J. Pain 14 2013 205 214
101. L. Zhou, A. Messing, and S.Y. Chiu Determinants of excitability at transition zones in Kv1.1-deficient myelinated nerves J. Neurosci. 19 1999 5768 5781